Industry News

FDA Advisory Committee Reviews Merck Chickenpox Vaccine

Published in Vaccine Weekly, February 13th, 1995

The licensing of a chickenpox vaccine is another step closer to becoming a reality.

On January 27, 1995, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biologicals Products Committee met to discuss issues related to the varicella-zoster virus vaccine live, developed by Merck and Company Inc., White House Station, New Jersey. Merck has named the vaccine Varivax.

The Vaccines and Related Biologicals Products Committee, a group of outside experts, previously had advised the FDA to look into several issues before making a final decision on approval, indicated Monica Revelle, spokesperson for the FDA.

Questions that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry